Bio-Technopark

In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 100,000 m2 of laboratory, production and office space is now leased to around 60 companies and organizations, and 80 academic research groups. Video

read more

Leasing

In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with partly shared infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.

read more

Services

The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.

 

read more

News

SecureCell launches Numera 3 sampling system

Urdorf, Zurich — SecureCell has launched the Numero 3 automated sampling system. The system enables laboratories to reduce their manual workload and generate more reliable data. A webinar on October 15 will discuss the advantages of the Numero 3 system. The biotech company SecureCell AG, based in Urdorf, has further developed...

read more

CUTISS closes CHF 56M Series C round and signs agreement with leading EU burn center

Switzerland, 10 September 2025 – CUTISS, a late-stage clinical TechBio at the forefront of tissue therapeutics and regenerative medicine, has announced the closing of its Series C round for a total of CHF 56M with existing and new investors, bringing total funds raised to more than CHF 125M. The proceeds will...

read more

Events

  • Bio-Technopark After Work Networking Aperitif
    07.10.2025